Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 19/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 16/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 11/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9151421 | 0.81 | ALDH1A1 (0.43) | CYP2D6 | |
| SCHEMBL18300145 | 0.74 | KDM1A (0.36) | SLC6A2SLC6A4 | |
| SCHEMBL23435139 | 0.74 | SLC6A2 (0.40) | SLC6A2SLC6A4CYP2D6SLC6A3 | |
| SCHEMBL7403358 | 0.73 | BCHE (0.40) | SLC6A2SLC6A4CYP2D6SLC6A3 | |
| SCHEMBL3216781 | 0.72 | SLC6A2 (0.40) | SLC6A2SLC6A4CYP2D6SLC6A3 | |
| SCHEMBL6382455 | 0.72 | NPC1 (0.40) | SLC6A2SLC6A4CYP2D6SLC6A3 | |
| SCHEMBL27415175 | 0.72 | HTR2A (0.39) | SLC6A2SLC6A4CYP2D6SLC6A3 | |
| SCHEMBL28436751 | 0.71 | BCHE (0.38) | SLC6A2SLC6A4CYP2D6SLC6A3 | |
| SCHEMBL10616744 | 0.71 | TOP2A (0.33) | — | |
| SCHEMBL19810459 | 0.71 | SLC6A2 (0.38) | SLC6A2SLC6A4CYP2D6SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944663-B2 | Process for preparing substituted pentacenes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2018-04-17 | — | — | US | claimed |
| US-20120305854-A1 | PROCESS FOR PREPARING SUBSTITUTED PENTACENES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-06 | — | — | US | claimed |
| US-8318048-B2 | Process for preparing substituted pentacenes | MERCK PATENT GMBH (DE) | 2012-11-27 | — | — | US | claimed |
| EP-2134725-B1 | PROCESS FOR PREPARING SUBSTITUTED PENTACENES | MERCK PATENT GMBH (DE) | 2012-07-04 | — | — | EP | claimed |
| US-20100127220-A1 | Process for Preparing Substituted Pentacenes | MERCK PATENT GMBH (DE) | 2010-05-27 | — | — | US | claimed |
| EP-2134725-A1 | PROCESS FOR PREPARING SUBSTITUTED PENTACENES | Merck Patent GmbH (DE) | 2009-12-23 | — | — | EP | claimed |
| WO-2008128618-A1 | PROCESS FOR PREPARING SUBSTITUTED PENTACENES | MERCK PATENT GMBH (DE) | 2008-10-30 | — | — | WO | claimed |
| CN-111004250-B | Synthetic method of 1, 4-epoxy-2, 3-dicyano-1, 2,3, 4-tetrahydronaphthalene | 江苏广域化学有限公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-111004250-A | Synthetic method of 1, 4-epoxy-2, 3-dicyano-1, 2,3, 4-tetrahydronaphthalene | 江苏广域化学有限公司 | 2020-04-14 | — | — | CN | disclosed |
| US-10174005-B2 | Fused pyrimidines as inhibitors of p97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-9944663-B2 | Process for preparing substituted pentacenes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2018-04-17 | — | — | US | disclosed |
| US-20180044325-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. | 2018-02-15 | — | — | US | disclosed |
| US-20120305854-A1 | PROCESS FOR PREPARING SUBSTITUTED PENTACENES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-06 | — | — | US | disclosed |
| WO-2004106316-A1 | METHOD FOR PRODUCING ALKOXYLATED 2,5-DIHYDROFURAN OR TETRA-1,1,4,4-ALKOXYLATED BUT-2-ENE DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2004-12-09 | — | — | WO | disclosed |
| EP-0843966-B1 | Preparation of aqueous solutions comprising o-phthalaldehyde and glutaraldehyde | DSM FINE CHEM AUSTRIA GMBH (AT) | 2002-09-11 | — | — | EP | disclosed |
| EP-0839789-B1 | Process for the purification of o-phthalic dialdehyde | DSM FINE CHEM AUSTRIA GMBH (AT) | 1999-12-15 | — | — | EP | disclosed |
| US-5874637-A | FORMING DIALKOXYPHTHALAN BY ACIDIFICATION, ADDING ALKALINE SOLUTION, SOLVENT EXTRACTION, DISTILLATION, HYDROLYSIS AND CONVERTING BACK TO O-PHTHALALDEHYDE | DSM CHEMIE LINZ GMBH (AT) | 1999-02-23 | — | — | US | disclosed |
| US-5872153-A | Process for preparing aqueous o-phthalaldehyde-glutaraldehyde solutions | DSM CHEMIE LINZ GMBH (AT) | 1999-02-16 | — | — | US | disclosed |
| EP-0843966-A1 | Preparation of aqueous solutions comprising o-phthalaldehyde and glutaraldehyde | DSM Chemie Linz GmbH (AT) | 1998-05-27 | — | — | EP | disclosed |
| EP-0839789-A1 | Process for the purification of o-phthalic dialdehyde | DSM Chemie Linz GmbH (AT) | 1998-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174005-B2 | Fused pyrimidines as inhibitors of p97 complex | WDR77, POP1, PSMG3 | SLC6A2 4091/4885SLC6A4 4129/4885CYP2D6 2699/4885 |
| US-20180044325-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | WDR77, POP1, PSMG3 | SLC6A2 4071/4885SLC6A4 4118/4885CYP2D6 2685/4885 |
| US-20100127220-A1 | Process for Preparing Substituted Pentacenes | FES, PFAS, SLC46A1 | SLC6A2 161/4885SLC6A4 35/4885CYP2D6 2374/4885 |
| US-20120305854-A1 | PROCESS FOR PREPARING SUBSTITUTED PENTACENES | FES, PFAS, SLC46A1 | SLC6A2 161/4885SLC6A4 35/4885CYP2D6 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.